Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an ...

Kaustubh Bagalkote Editas Q2 Earnings & Revenues Miss Estimates, Stock Down Editas Medicine, Inc. (NASDAQ: EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $412.45, moving -0.49% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.12% ...

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is a large-cap stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the ...

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals ...

Investors should also note that VRTX has a PEG ratio of 837.5 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected ...

This was the stock's second consecutive day of losses.